The Wall Street Journal covers the Laura and John Arnold Foundation’s $5.2 million grant to ICER to fund evaluations of the clinical- and cost-effectiveness of new, expensive drug therapies. The evaluations will also determine a value-based price benchmark at which new therapies would provide optimal value to the health care system. Read the article here (subscription may be required).